Search alternatives:
significantly increased » significant increase (Expand Search)
increased decrease » increased release (Expand Search), increased crash (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
small decrease » small increased (Expand Search)
significantly increased » significant increase (Expand Search)
increased decrease » increased release (Expand Search), increased crash (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
small decrease » small increased (Expand Search)
-
3061
-
3062
-
3063
-
3064
-
3065
The Laboratory Animal Flow Diagram.
Published 2025“…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
-
3066
<sup>1</sup>H NMR spectra for kylo-0603.
Published 2025“…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
-
3067
<sup>13</sup>C NMR spectra for Kylo-0603.
Published 2025“…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
-
3068
The structures of T3 and Kylo-0603.
Published 2025“…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
-
3069
Synthesis process of Kylo-0603.
Published 2025“…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
-
3070
ESI-HRMS spectra for Kylo-0603.
Published 2025“…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
-
3071
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
3072
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
3073
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
3074
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
3075
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
3076
-
3077
-
3078
-
3079
-
3080
Probability density of farmers’ production and operation income in two cases.
Published 2025Subjects: